Chembio Diagnostics Revenue 2006-2018 | CEMI

Chembio Diagnostics revenue from 2006 to 2018. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
Chembio Diagnostics Annual Revenue
(Millions of US $)
2018 $33
2017 $24
2016 $18
2015 $24
2014 $28
2013 $30
2012 $26
2011 $19
2010 $17
2009 $14
2008 $11
2007 $9
2006 $7
2005 $4
Chembio Diagnostics Quarterly Revenue
(Millions of US $)
Q4 2018 $8
Q3 2018 $9
Q2 2018 $9
Q1 2018 $8
Q4 2017 $6
Q3 2017 $8
Q2 2017 $4
Q1 2017 $6
Q4 2016 $4
Q3 2016 $4
Q2 2016 $3
Q1 2016 $7
Q4 2015 $4
Q3 2015 $7
Q2 2015 $7
Q1 2015 $6
Q4 2014 $7
Q3 2014 $7
Q2 2014 $7
Q1 2014 $6
Q4 2013 $8
Q3 2013 $10
Q2 2013 $5
Q1 2013 $7
Q4 2012 $8
Q3 2012 $5
Q2 2012 $6
Q1 2012 $7
Q4 2011 $6
Q3 2011 $6
Q2 2011 $4
Q1 2011 $4
Q4 2010 $6
Q3 2010 $5
Q2 2010 $4
Q1 2010 $3
Q4 2009 $4
Q3 2009 $4
Q2 2009 $3
Q1 2009 $3
Q4 2008 $2
Q3 2008 $4
Q2 2008 $3
Q1 2008 $2
Q4 2007 $2
Q3 2007 $2
Q2 2007 $3
Q1 2007 $2
Q4 2006 $3
Q3 2006 $1
Q2 2006 $2
Q1 2006 $1
Q4 2005 $1
Q3 2005 $1
Q2 2005 $1
Q1 2005 $1
Sector Industry Market Cap Revenue
Medical Medical Products Manufacturing $0.094B $0.033B
CHEMBIO DIAGNOSTICS, INC. develops, manufactures, licenses and markets proprietary rapid diagnostic tests in the growing $5 billion point-of-care testing market. Chembio's two FDA PMA-approved, CLIA-waived, rapid HIV tests are marketed in the U.S. by a third party company. Chembio markets its HIV STAT-PAK line of rapid HIV tests internationally to government and donor-funded programs directly and through distributors. Chembio also has rapid tests for veterinary tuberculosis and chagas disease. In 2007 Chembio received a U.S. patent for its Dual Path Platform technology which has significant advantages over lateral-flow technologies. This technology is providing Chembio with a significant pipeline of business opportunities for the development and manufacture of new products based on DPP. Chembio is licensed by the U.S. Food and Drug Administration as well as the U. S. Department of Agriculture, and is certified for the global market under the International Standards Organization directive 13.485.
Stock Name Country Market Cap PE Ratio
Abbott Laboratories (ABT) United States $137.409B 27.16
Medtronic (MDT) Ireland $121.535B 17.77
Stryker (SYK) United States $72.819B 26.70
Boston Scientific (BSX) United States $52.168B 25.43
Baxter (BAX) United States $39.788B 25.45
Zimmer Biomet Holdings (ZBH) United States $25.879B 16.57
Smith & Nephew SNATS (SNN) United Kingdom $17.424B 0.00
Canopy Growth (CGC) Canada $14.802B 0.00
ResMed (RMD) United States $14.533B 27.56
Aurora Cannabis (ACB) Canada $9.364B 66.07
Bio-Rad Laboratories (BIO) United States $9.204B 52.51
Hill-Rom Holdings (HRC) United States $6.966B 21.55
Perrigo (PRGO) Ireland $6.355B 10.30
Insulet (PODD) United States $5.761B 1943.60
GW Pharmaceuticals (GWPH) United Kingdom $4.977B 0.00
ICU Medical (ICUI) United States $4.744B 29.53
Haemonetics (HAE) United States $4.355B 38.63
Hutchison China MediTech (HCM) China $3.802B 0.00
Agios Pharmaceuticals (AGIO) United States $3.664B 0.00
Neogen (NEOG) United States $3.153B 48.42
NuVasive (NUVA) United States $2.938B 25.63
Quidel (QDEL) United States $2.527B 22.80
Aphria (APHA) $2.418B 107.33
National Vision Holdings (EYE) United States $2.298B 45.20
Cardiovascular Systems (CSII) United States $1.337B 960.00
HEXO (HEXO) $1.317B 0.00
VAREX IMAGING (VREX) United States $1.274B 24.95
Phibro Animal Health (PAHC) United States $1.273B 18.29
AtriCure (ATRC) United States $1.095B 0.00
MacroGenics (MGNX) United States $0.957B 0.00
Lantheus Holdings (LNTH) United States $0.914B 24.70
Cerus (CERS) United States $0.842B 0.00
Omeros (OMER) United States $0.836B 0.00
PetIQ (PETQ) United States $0.835B 23.90
NanoString Technologies (NSTG) United States $0.726B 0.00
Meridian Bioscience (VIVO) United States $0.716B 21.32
Eagle Pharmaceuticals (EGRX) United States $0.674B 22.95
OraSure Technologies (OSUR) United States $0.671B 29.41
TG Therapeutics (TGTX) United States $0.619B 0.00
LeMaitre Vascular (LMAT) United States $0.587B 27.92
Evolus (EOLS) United States $0.577B 0.00
Surmodics (SRDX) United States $0.556B 80.90
Quanterix (QTRX) United States $0.531B 0.00
BioLife Solutions (BLFS) United States $0.350B 144.46
Insys Therapeutics (INSY) United States $0.342B 0.00
Vapotherm (VAPO) United States $0.335B 0.00
Rockwell Medical (RMTI) United States $0.325B 0.00
Utah Medical Products (UTMD) United States $0.313B 20.33
Bovie Medical (APYX) United States $0.271B 0.00
Owens & Minor (OMI) United States $0.265B 3.67
Neptune Technologies & Bioresources Inc (NEPT) Canada $0.242B 0.00
Cytosorbents (CTSO) United States $0.237B 0.00
Zynex (ZYXI) United States $0.142B 15.21
Fonar (FONR) United States $0.140B 7.48
Surface Oncology (SURF) United States $0.123B 0.00
Chimerix (CMRX) United States $0.103B 0.00
Female Health (VERU) United States $0.097B 0.00
InfuSystems Holdings (INFU) United States $0.089B 0.00
United-Guardian (UG) United States $0.087B 20.02
CAS Medical Systems (CASM) United States $0.071B 0.00
Neurotrope (NTRP) United States $0.067B 0.00
Trinity Biotech (TRIB) Ireland $0.062B 18.50
Oramed Pharmaceuticals (ORMP) United States $0.056B 0.00
ImmuCell (ICCC) United States $0.038B 0.00
Conatus Pharmaceuticals (CNAT) United States $0.036B 0.00
Valeritas Holdings (VLRX) United States $0.033B 0.00
Senestech (SNES) United States $0.032B 0.00
Myomo (MYO) United States $0.021B 0.00
Capricor Therapeutics (CAPR) United States $0.017B 0.00
InVivo Therapeutics Holdings (NVIV) United States $0.015B 0.00
Akers Biosciences Inc (AKER) United States $0.012B 0.00
Cellectar Biosciences (CLRB) United States $0.011B 0.00
NeuroMetrix (NURO) United States $0.008B 15.14